Elicio Therapeutics, Inc.
Moat Score — Elicio Therapeutics, Inc.
Total Moat Score
5 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | Elicio's AMP amphiphile platform is protected by patents licensed from MIT plus company-owned filings covering mKRAS, BRAF, TP53 and CpG amphiphile technology, with expirations extending to 2037-2046, giving meaningful scientific and legal protection to its core technology. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | As a pre-revenue clinical-stage company with no commercial manufacturing scale and full reliance on contract manufacturers, Elicio has no demonstrated cost advantage versus peers. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 0 / 5 | With no approved or marketed product, Elicio has no current pricing power; any future pricing power is entirely speculative and contingent on clinical success and eventual payer negotiations. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Immunotherapy drug development exhibits no network effects; the platform's value does not increase with the number of users or prescribers. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 0 / 5 | There is no commercial product in use today, so no physician, payer, or patient switching costs exist yet. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | The off-the-shelf, common-mutation-targeting design and reliance on standard synthetic chemistry CMOs could allow efficient manufacturing scale-up if approved, but this remains unproven and the addressable niches (e.g., mKRAS PDAC) are still being defined clinically. |